fluorobenzenes has been researched along with Cardiovascular Diseases in 246 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.41) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 113 (45.93) | 29.6817 |
| 2010's | 131 (53.25) | 24.3611 |
| 2020's | 1 (0.41) | 2.80 |
| Authors | Studies |
|---|---|
| Bots, ML; Chen, Y; Fu, L; Hu, B; Hu, H; Karlson, BW; Li, H; Li, X; Li, Z; Meng, X; Nie, Z; Wang, Y; Wei, D; Zhao, B; Zheng, H | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Boekholdt, SM; Kastelein, JJ; Khaw, KT; Rana, JS; Sondermeijer, BM; Wareham, NJ | 1 |
| Barter, PJ; Chapman, MJ; Giral, P | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A | 1 |
| Postmus, I; Trompet, S; Wouter Jukema, J | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 2 |
| Kang, HC; Kim, CM; Kim, YS; Lee, JA; Lee, SY; Oh, HJ; Park, KC; Sin, DH; Sunwoo, S; Yang, YJ; Yu, BY | 1 |
| Khanna, D; Mahalwar, R | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Barratt, BJ; Chasman, DI; Danik, JS; MacFadyen, JG; Nyberg, F; Ridker, PM | 1 |
| Bots, ML; de Korte, C; den Ruijter, HM; Groenewegen, KA; Lind, L; Peters, SA | 1 |
| Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Glynn, RJ; Mora, S; Ridker, PM | 1 |
| Bae, JH; Bae, JW; Cha, MJ; Chae, IH; Cho, MC; Kim, HS; Kwon, TG; Lee, SP; Rha, SW; Suh, JW | 1 |
| Caulfield, MP; Everett, BM; Hantash, FM; Khera, AV; Mora, S; Ridker, PM; Wohlgemuth, J | 2 |
| Debanne, SM; Eckard, AR; Funderburg, NT; Jiang, Y; McComsey, GA | 1 |
| Dubé, MP | 1 |
| Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C | 1 |
| Ridker, PM; van der Graaf, Y; van der Leeuw, J; Visseren, FL | 1 |
| Kronenberg, F | 1 |
| Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N | 1 |
| Berger, H; Englert, H; Grittner, U; Katus, HA; Muckelbauer, R; Müller-Nordhorn, J; Prugger, C; Sonntag, F; Völler, H; Wegscheider, K; Willich, SN | 1 |
| Toth, PP | 1 |
| Ashton, V; Marrett, E; Neff, D; Ramey, DR; Tershakovec, AM; Zhang, NJ; Zhang, Q; Zhao, C | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 1 |
| Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG | 1 |
| Chen, J; Li, P; Liang, X; Lin, Z; Mo, Y; Wang, Z; Xie, W | 1 |
| Chapman, MJ; Giral, P; Simon, D | 1 |
| Debanne, SM; Erlandson, KM; Jiang, Y; McComsey, GA | 1 |
| Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK | 1 |
| Adams, SP; Sekhon, SS; Wright, JM | 1 |
| Ban, MR; Hegele, RA; Ibrahim, C | 1 |
| Debanne, S; Dirajlal-Fargo, S; Hileman, CO; Jiang, Y; Kinley, B; Longenecker, CT; McComsey, GA | 1 |
| Laufs, U | 1 |
| Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE | 1 |
| Drapkina, OM; Eliashevich, SO | 1 |
| Hu, YZ; Wu, YX; Yang, Y | 1 |
| Eaton Md, CB | 1 |
| Erdmann, E; Hoppe, UC | 1 |
| Kapur, NK; Musunuru, K | 1 |
| Barillà, F; Donato, L; Petrini, N; Pulcinelli, FM; Riondino, S; Tanzilli, G; Torromeo, C | 1 |
| Nicholls, SJ | 1 |
| Kastelein, JJ; Marck, R; Meuwese, MC; Mooij, HL; Nieuwdorp, M; Stroes, ES; van Lith, B; Vink, H | 1 |
| Hlatky, MA | 1 |
| Danielson, E; Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT | 3 |
| Couzin, J | 1 |
| Koenig, W | 1 |
| Glynn, RJ; MacFadyen, JG; Ridker, PM | 1 |
| Mitka, M | 2 |
| Parhofer, K | 1 |
| Einecke, D | 1 |
| Gagne, JJ; Polinski, JM | 1 |
| Riesen, WF | 1 |
| Lüscher, TF | 1 |
| Coradi, B | 1 |
| Scheen, AJ | 1 |
| Devaraj, S; Jialal, I | 1 |
| Berneis, K; Kapur, NK; Rini, GB; Rizzo, M; Spinas, GA | 1 |
| Bansilal, S; Fuster, V | 1 |
| Nissen, SE | 1 |
| Campion, EW; Kritek, P | 1 |
| Gibbons, RJ | 1 |
| Fugh-Berman, A | 1 |
| Chan, PS; Hayward, RA; Nallamothu, BK | 1 |
| Chan, ES; Mak, KH | 1 |
| Jenny-Avital, ER | 1 |
| Bucher, HC; Koller, MT; Steyerberg, EW | 1 |
| Pierard, LA | 1 |
| Davis, CE | 1 |
| Lubsen, J | 1 |
| Koopmans, RP | 1 |
| Bredie, B | 1 |
| Blumenthal, RS; Michos, ED | 1 |
| Berneis, K; Rini, GB; Rizzo, M; Spinas, GA | 1 |
| Després, JP | 1 |
| Craig, JC; Strippoli, GF | 1 |
| Bannister, K; Beutler, J; Chae, DW; Chevaile, A; Cobbe, SM; De Lima, JJ; Fellström, BC; Gottlow, M; Grönhagen-Riska, C; Holdaas, H; Jardine, AG; Johnsson, E; Lins, R; Mayer, G; McMahon, AW; Parving, HH; Remuzzi, G; Samuelsson, O; Schmieder, RE; Sci, D; Sonkodi, S; Süleymanlar, G; Tesar, V; Todorov, V; Tsakiris, D; Wiecek, A; Wüthrich, RP; Zannad, F | 1 |
| Keba, E; Laks, T; Leiner, M; Merilind, E; Otter, K; Petersen, M; Reinmets, S; Sööt, T; Väli, S | 1 |
| Bosch, J; Lonn, E; Yusuf, S | 1 |
| Davidson, MH; Friedewald, VE; Ridker, PM; Roberts, WC; Willerson, JT | 1 |
| Gentile, M; Marotta, G; Rubba, P | 1 |
| Fabbri, G; Maggioni, AP | 1 |
| Kones, R | 2 |
| Narkiewicz, K | 1 |
| Bell, DS; Carter, MD; Lavie, CJ; O'Keefe, JH | 1 |
| Ridker, PM | 5 |
| Gaspardone, A; Maseri, A | 1 |
| Wheeler, DC | 1 |
| Güleç, S | 1 |
| Ganguli, A | 1 |
| Danchin, N | 1 |
| de Tena, JG | 1 |
| Feeman, WE | 1 |
| Bloom, JM | 1 |
| Parra, D; Rosenstein, R | 1 |
| Sniderman, AD | 1 |
| Ruilope, LM; Segura, J | 1 |
| Kassimatis, TI; Konstantinopoulos, PA | 1 |
| de Oliveira, JM | 1 |
| Watson, KE | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Stewart, RA | 1 |
| Plonk, WM | 1 |
| Heintjes, EM; Herings, RM; Johansson, S; Penning-van Beest, FJ; Stalenhoef, AF | 1 |
| Fonseca, FA; Izar, MC | 1 |
| Jones, JK; Ming, EE; Motsko, SP; Russmann, S; Singh, VP; Vendiola, RM | 1 |
| Bell, DS; O'Keefe, JH | 1 |
| Katona, A; Márk, L | 1 |
| Barrios, V; Escobar, C | 1 |
| Amsterdam, EA; Kappagoda, CT | 1 |
| Fricker, J | 1 |
| Couzin-Frankel, J | 1 |
| Blaha, MJ; Blumenthal, RS; Michos, ED; Narla, V | 1 |
| Eren, M | 1 |
| Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M | 1 |
| Allan, GM; McCormack, JP | 1 |
| Blumenthal, R; Duvernoy, CS | 1 |
| Macias, JF; Robles, NR | 1 |
| Accad, M; Fred, HL | 1 |
| Bajpai, A; Goyal, A; Sperling, L | 1 |
| Glynn, RJ; Koenig, W; Nordestgaard, BG; Ridker, PM; Shepherd, J | 1 |
| Ouyang, P; Zieman, SJ | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Glynn, RJ; Ridker, PM | 2 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Abramson, J; de Lorgeril, M; Dodin, S; Hamazaki, T; Kostucki, W; Okuyama, H; Pavy, B; Rabaeus, M; Salen, P | 1 |
| Fox, KM; Gandhi, SK; Gold, A; Hsia, J; Jensen, MM; Ohsfeldt, RL; Smolen, LJ | 1 |
| Genest, J; Glynn, RJ; Kastelein, JJ; Koenig, W; Macfadyen, JG; Nordestgaard, BG; Ridker, PM | 1 |
| MacDonald, GP | 2 |
| Addo, J; Cappuccio, FP; Casas, JP; Hingorani, AD; Jeffery, S; Miller, MA; Newcombe, P; Shah, T; Smeeth, L; Strazzullo, P; Tinworth, L; Whittaker, J | 1 |
| Pietanza, SC; Schena, FP; Vassanelli, C | 1 |
| Carter, NJ | 1 |
| Cornuz, J; Marques-Vidal, PM; Nanchen, D; Paccaud, F; Pletcher, MJ; Rodondi, N; Vollenweider, P; Waeber, G | 1 |
| Eisenberg, T; Wells, MT | 1 |
| Biron, P; Rose, CP; Vos, E | 1 |
| Crea, F; Sgueglia, GA | 1 |
| Breimer, LH; Mikhailidis, DP | 1 |
| Gallo, P; Rapezzi, C | 1 |
| Gambetti, S; Romanazzi, S; Urbinati, S | 1 |
| Perna, GP | 1 |
| Chu, KM; Han, CL; Li, YH; Lin, GM | 1 |
| Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS | 1 |
| Blaha, MJ; Blumenthal, RS; Long, SB; Michos, ED | 1 |
| Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; Criqui, MH; Cushman, M; Lakoski, S; Nasir, K; O'Leary, DH; Rivera, JJ; Szklo, M | 1 |
| Hsia, J; MacFadyen, JG; Monyak, J; Ridker, PM | 1 |
| Chasman, DI; Glynn, RJ; MacFadyen, JG; Ridker, PM | 1 |
| Elis, A; Stein, EA; Zhou, R | 1 |
| Targher, G | 1 |
| Albert, MA; Ferdinand, KC; Fonseca, FA; Glynn, RJ; Lorenzatti, AJ; MacFadyen, JG; Ridker, PM | 1 |
| Diamond, GA; Kaul, S; Morrissey, RP | 1 |
| Day, S | 1 |
| Breckenridge, A | 1 |
| Temple, R | 1 |
| Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; DeFilippis, AP; Lima, J; Nasir, K; O'Leary, DH; Rivera, JJ | 1 |
| Allemann, Y; Burow, A; Hess, OM; Klaey, M; Shaw, SG; Wustmann, K | 1 |
| Cook, NR; Dorresteijn, JA; Paynter, NP; Ridker, PM; Steyerberg, EW; van der Graaf, Y; Visseren, FL; Wassink, AM | 1 |
| Palomo, L; Sánchez-Robles, G | 1 |
| Gandhi, SK; Jensen, MM; Ohsfeldt, RL; Olsson, AG; Paulsson, T | 1 |
| Kataoka, Y; Nicholls, SJ; Uno, K | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Serebruany, VL | 1 |
| Anand, IS | 1 |
| Kobalava, ZhD; Villeval'de, SV | 1 |
| Barratt, BJ; Chasman, DI; Chu, AY; Guilianini, F; Nyberg, F; Ridker, PM | 1 |
| Crook, MA; Jewkes, C; Jones, A; Meek, C; Twomey, PJ; Viljoen, A; Wierzbicki, AS | 1 |
| Ahn, YK; Baek, SH; Byun, YS; Cho, KI; Choi, DJ; Choi, SW; Choi, YS; Jang, Y; Jeon, DW; Kim, JY; Kim, KS; Kim, YJ; Lee, SH; Min, PK; Rha, SW | 1 |
| Athyros, VG; Karagiannis, A; Kostapanos, MS; Mikhailidis, DP | 1 |
| Barratt, BJ; Chasman, DI; Giulianini, F; MacFadyen, J; Nyberg, F; Ridker, PM | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Stein, EA | 1 |
| Koenig, W; MacFadyen, JG; Ridker, PM; Wolfert, RL | 1 |
| Agouridis, AP; Challa, A; Elisaf, M; Liberopoulos, EN; Makariou, SE | 1 |
| Almog, Y; Glynn, RJ; MacFadyen, J; Malhotra, A; Novack, V; Ridker, PM | 1 |
| Boekholdt, SM; Glynn, RJ; Kastelein, JJ; Mora, S; Nordestgaard, BG; Ridker, PM | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Kasmas, SH; Mendes, GD; Pinheiro, LF; Povoa, RM | 1 |
| Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Elis, A; Lishner, M | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Hudzik, B; Polonski, L; Szkodzinski, J | 1 |
| Colotto, M; Durante, C; Renzi, A | 1 |
| Gogolashvili, NG | 1 |
| Ooi, EM; Watts, GF | 1 |
| Glynn, RJ; Libby, P; MacFadyen, JG; Pradhan, A; Ridker, PM | 1 |
| Jeong, JW; Kim, NH; Ko, JS; Oh, SK; Rhee, SJ; Shin, SN; Yun, KH | 1 |
| Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A | 1 |
| Drapkina, OM; Korneeva, ON | 1 |
| Cunha, RV; Domingos, H; Domingos, JA; Paniago, AM; Rodrigues, RL; Souza, AS | 1 |
| Brito, JP; Montori, VM | 1 |
| Carney, SL | 1 |
| Zateĭshchikov, DA | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Bernal-Rosales, LP; Cervantes, JL; Gonzalez, JG; Marin, JA; Martinez, G; Ocampo, R; Polanco, A; Rodriguez-Briones, I; Sanchez-Mijangos, H; Talavera, JO | 1 |
| Korlipara, K | 1 |
| Owen, OG | 1 |
| Olsson, A | 1 |
| Baldasseroni, S; Fabbri, G; Maggioni, AP | 1 |
| Fox, JC; Schuster, H | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Ferdinand, KC | 1 |
| Dunselman, PH; Jukema, JW; Liem, AH; Lok, DJ; van der Sloot, JA; Zwinderman, AH | 1 |
| Mora, S; Ridker, PM | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Berneis, K; Rizzo, M | 1 |
| Borok, GM; Huse, DM; McDonough, K; Ozminkowski, RJ; Song, X; Williams, SA | 1 |
| Borok, GM; Huse, DM; Maguire, J; McDonough, K; Ozminkowski, RJ; Song, X; Williams, SA | 1 |
| De Hert, M; Hanssens, L; Kalnicka, D; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Ballantyne, CM; Duffield, E; Eber, B; Moccetti, T; Sosef, F; Vogt, A; Weiss, R | 1 |
| Schuster, H | 1 |
| Stahl, HD | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, A; Van der Bom, JG; Van Tol, A | 1 |
| Apetrei, E; Barrios, V; Böhm, M; Cleland, JG; Cornel, JH; Dunselman, P; Fonseca, C; Goudev, A; Grande, P; Gullestad, L; Hjalmarson, A; Hradec, J; Jánosi, A; Kamenský, G; Kjekshus, J; Komajda, M; Korewicki, J; Kuusi, T; Mach, F; Mareev, V; McMurray, JJ; Ranjith, N; Schaufelberger, M; van Veldhuisen, DJ; Vanhaecke, J; Waagstein, F; Wedel, H; Wikstrand, J | 1 |
| Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA | 1 |
| Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Orr, JD | 1 |
| Angermann, CE; Nitschmann, S | 1 |
| Elisaf, MS; Kostapanos, MS; Milionis, HJ | 1 |
| Doggrell, SA | 1 |
| Gandhi, S; Harley, CR; Heien, H; Nelson, SP | 1 |
| Bruckert, E | 1 |
| Frishman, WH; Murthy, S; Strom, JA | 1 |
55 review(s) available for fluorobenzenes and Cardiovascular Diseases
| Article | Year |
|---|---|
Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Fluorobenzenes; Humans; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
An update on the benefits and risks of rosuvastatin therapy.
Topics: Atherosclerosis; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Lipid-lowering efficacy of rosuvastatin.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
[Lipid lowering by rosuvastatin: how do statins differ?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2015 |
[Choosing wisely when prescribing statins].
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
[Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Diseases].
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morbidity; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Russia; Secondary Prevention; Sulfonamides; Treatment Outcome | 2015 |
Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Kidney Injury; Cardiac Catheterization; Cardiovascular Diseases; Contrast Media; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2015 |
[Cardiology 2008].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Cardiac Catheterization; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Fluorobenzenes; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
Clinical efficacy and safety of statins in managing cardiovascular risk.
Topics: Atherosclerosis; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
Rosuvastatin and progression of atherosclerosis.
Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Coronary Vessels; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Lipid lowering for primary prevention.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Meta-Analysis as Topic; Primary Prevention; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome | 2009 |
Efficacy and safety of rosuvastatin in the management of dyslipidemia.
Topics: Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome | 2009 |
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Kidney Failure, Chronic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Topics: Angina, Unstable; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome | 2009 |
The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Gravity Sensing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Moving toward new statin guidelines in a post-JUPITER world: principles to consider.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
[The JUPITER trial: a new approach in primary prevention].
Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
The JUPITER trial: How will it change clinical practice?
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.
Topics: Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rediscovering bile acid sequestrants.
Topics: Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fluorobenzenes; Humans; Hypoglycemic Agents; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
[From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
Topics: Aged; Atherosclerosis; Attitude of Health Personnel; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Prescriptions; Family Practice; Female; Fluorobenzenes; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Expectancy; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
[The role of statins in the treatment of heart failure].
Topics: Cardiovascular Diseases; Coronary Disease; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Cardiovascular risk in uremic patients: darkness after AURORA.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Patient Dropouts; Patient Selection; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides; Uremia | 2010 |
Should we measure C-reactive protein on earth or just on JUPITER?
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction.
Topics: C-Reactive Protein; Cardiovascular Diseases; Ethnicity; Europe; Fluorobenzenes; Genetics, Population; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymorphism, Single Nucleotide; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States | 2010 |
Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.
Topics: Aged; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides | 2011 |
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Statins in primary prophylaxis of cardiovascular diseases].
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Primary Prevention; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2012 |
Non-every day statin administration--a literature review.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
Topics: Atorvastatin; Biological Availability; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Therapeutic Equivalency | 2012 |
[How to prolong life of patients at high cardiovascular risk. Features of rosuvastatin].
Topics: Cardiovascular Diseases; Fluorobenzenes; Global Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2012 |
[Features of the use of rosuvastatin in clinical practice].
Topics: Biological Availability; Cardiovascular Diseases; Comorbidity; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Metabolic Clearance Rate; Pharmacogenetics; Pharmacovigilance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tissue Distribution; Treatment Outcome | 2012 |
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2003 |
Statins: how far have we come? A review of rosuvastatin.
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Ongoing trials and future prospects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Interactions; Drug Labeling; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Product Surveillance, Postmarketing; Pyrimidines; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Rosuvastatin Calcium; Sulfonamides | 2005 |
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
The clinical relevance of low-density-lipoproteins size modulation by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation Mediators; Male; Maximum Tolerated Dose; Program Evaluation; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides | 2007 |
Statins in the spectrum of neurologic disease.
Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides | 2008 |
An overview of the extra-lipid effects of rosuvastatin.
Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Central Nervous System; Fibrinolytic Agents; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Nervous System; Peripheral Nervous System; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
New advances in lipid-modifying therapies for reducing cardiovascular risk.
Topics: Acetamides; Acetates; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sulfonic Acids | 2002 |
Ultra-short-acting beta-adrenergic blockers.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Fluorobenzenes; Humans; Hypotension; Propanolamines | 1988 |
50 trial(s) available for fluorobenzenes and Cardiovascular Diseases
| Article | Year |
|---|---|
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Fluorobenzenes; Humans; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2022 |
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2013 |
Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides; Surveys and Questionnaires | 2013 |
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Topics: Alleles; Cardiovascular Diseases; DNA; Double-Blind Method; Fluorobenzenes; Follow-Up Studies; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Primary Prevention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
The impact of variability in ultrasound settings on the measured echolucency of the carotid intima-media.
Topics: Adult; Calibration; Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Pyrimidines; Reproducibility of Results; Risk Factors; Rosuvastatin Calcium; Software; Sulfonamides; Time Factors | 2013 |
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult | 2013 |
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Topics: Aged; Angina, Unstable; Apolipoprotein A-I; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Endpoint Determination; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Proportional Hazards Models; Pyrimidines; Risk; Rosuvastatin Calcium; Single-Blind Method; Stroke; Sulfonamides; Triglycerides | 2013 |
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2014 |
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Topics: Aged; Black People; Cardiovascular Diseases; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoprotein(a); Male; Middle Aged; Placebos; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; White People | 2014 |
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anti-Retroviral Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Regression Analysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vasculitis | 2014 |
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.
Topics: Aged; Cardiovascular Diseases; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cytokines; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol Polyphosphate 5-Phosphatases; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; T-Lymphocytes, Regulatory | 2014 |
Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.
Topics: Absorptiometry, Photon; Adult; Biomarkers; Body Composition; Bone Density; Cardiovascular Diseases; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Osteoporosis; Pyrimidines; Receptors, Tumor Necrosis Factor, Type I; Regression Analysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2015 |
Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
Topics: Adult; Anti-Retroviral Agents; Anticholesteremic Agents; Cardiovascular Diseases; Enzyme-Linked Immunosorbent Assay; Female; Fluorobenzenes; HIV Infections; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Placebos; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2015 |
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides | 2008 |
Is hsCRP Back on Board? Implications from the JUPITER Trial.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.
Topics: Aged; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Data Interpretation, Statistical; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Sulfonamides | 2009 |
[JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2008 |
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) st
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Nutrition Surveys; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States | 2009 |
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sensitivity and Specificity; Statistics, Nonparametric; Sulfonamides; Treatment Outcome | 2009 |
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pulmonary Embolism; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism; Venous Thrombosis | 2009 |
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Failure | 2009 |
Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study.
Topics: Aged; Cardiovascular Diseases; Estonia; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Confidence Intervals; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk; Risk Assessment; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism | 2009 |
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvas
Topics: Aged; C-Reactive Protein; Canada; Cardiovascular Diseases; Cholesterol, LDL; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastati
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Topics: Aged; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Fluorobenzenes; Follow-Up Studies; Global Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prevalence; Primary Prevention; Pyrimidines; Racial Groups; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome | 2011 |
Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease.
Topics: Aged; Anticholesteremic Agents; Brachial Artery; Cardiovascular Diseases; Double-Blind Method; Endothelium; Endpoint Determination; Female; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vasodilation; Vitamin B Complex; Vitamins | 2012 |
Estimating treatment effects for individual patients based on the results of randomised clinical trials.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Data Interpretation, Statistical; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Biological; Models, Statistical; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
Topics: Apolipoproteins E; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Genome-Wide Association Study; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrimidines; Receptors, Lysophosphatidic Acid; Rosuvastatin Calcium; Sulfonamides | 2012 |
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Creatinine; Drug Combinations; Enzymes; Female; Fenofibrate; Fluorobenzenes; Hemoglobins; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Muscle, Skeletal; Patient Selection; Pyrimidines; Republic of Korea; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Genome-Wide Association Study; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Calcifediol; Cardiovascular Diseases; Combined Modality Therapy; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Pneumonia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Mexico; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
Topics: Cardiovascular Diseases; Data Collection; Double-Blind Method; Fluorobenzenes; Humans; Lipoproteins, LDL; Meta-Analysis as Topic; Pyrimidines; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2004 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Topics: Aged; Azetidines; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Rosuvastatin in older patients with systolic heart failure.
Topics: Aged; Cardiovascular Diseases; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Systole; Treatment Outcome | 2007 |
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2007 |
141 other study(ies) available for fluorobenzenes and Cardiovascular Diseases
| Article | Year |
|---|---|
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; England; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides | 2013 |
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER.
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Statins work around the world.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?
Topics: Anti-Retroviral Agents; Cardiovascular Diseases; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vasculitis | 2014 |
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects.
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Numbers Needed To Treat; Precision Medicine; Professional Practice; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides | 2014 |
Lipoprotein(a): there's life in the old dog yet.
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Longitudinal association between body mass index and health-related quality of life.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Obesity; Pyrimidines; Quality of Life; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; International Classification of Diseases; Male; Middle Aged; Pyrimidines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2014 |
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastati
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Pyrimidines; Sulfonamides | 2014 |
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Pyrimidines; Sulfonamides | 2014 |
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2015 |
The effect of infrequent low-dose rosuvastatin on the lipid profile.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk.
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2016 |
Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2009 |
I am 72, had a heart attack 16 years ago, and had angioplasty at Cleveland Clinic. My LDL was over 100 and HDL was in the low 30s. I take rosuvastatin and now my LDL is below 70, but my HDL has been driven down also, to 22. I am unable to raise HDL ind
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dextrans; Endothelium; Fluorobenzenes; Glycocalyx; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Permeability; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Expanding the orbit of primary prevention--moving beyond JUPITER.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Studies examine inflammatory biomarker in prevention and prediction of heart disease.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides | 2009 |
[Sequelae of the JUPITER study. What is changing in primary prevention? (interview by Dr. med. Dirk Einecke)].
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Statin cuts cardiovascular risk in half].
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2008 |
Concern still warranted: medication burden and persistence with lipid-lowering drugs.
Topics: C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
[Comment from the lipidologic viewpoint].
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Data Interpretation, Statistical; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the family practice viewpoint].
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Family Practice; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Jupiter to Earth: CRP promotes atherothrombosis.
Topics: Aged; Animals; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
JUPITER strikes earth.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
The Jupiter trial: key findings, controversies, and implications.
Topics: Aged; C-Reactive Protein; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Decision Making; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Study stirs debate about statin use in those without high cholesterol.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; United States | 2009 |
JUPITER clinical directions--polling results.
Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Laboratory Techniques; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Screening; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Asian People; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multivariate Analysis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Survival Analysis | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Bias; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides | 2009 |
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Topics: C-Reactive Protein; Cardiovascular Diseases; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2009 |
[JUPITER study (2). For now no reason to give statins to more people].
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2009 |
[Less vascular risk with rosuvastatin in elevated CRP].
Topics: C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Is diabetes the cost to pay for a greater cardiovascular prevention?
Topics: Cardiovascular Diseases; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Bringing JUPITER down to earth.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Global Health; Health Services Needs and Demand; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides | 2009 |
Sunset for statins after AURORA?
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Failure | 2009 |
The editor's roundtable: the JUPITER trial--initial results and clinical implications.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
[JUPITER study, more reason to give statins as preventive measure - commentary].
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Comorbidity; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Treatment Outcome | 2009 |
[The JUPITER study].
Topics: C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
The Jupiter trial--new territory for statins?
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients undergoing hemodialysis.
Topics: Cardiovascular Diseases; Confounding Factors, Epidemiologic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperphosphatemia; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Phosphorus; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Screening; Patient Selection; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Causality; Cholesterol, LDL; Confounding Factors, Epidemiologic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Polymorphism, Genetic; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Research Design; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin in patients undergoing hemodialysis.
Topics: Cardiovascular Diseases; Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients undergoing hemodialysis.
Topics: Age Factors; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Most would fail to benefit from JUPITER Intervention.
Topics: Adult; Aged; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Primary Prevention; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Statistics as Topic; Sulfonamides; Survival Analysis; United States | 2009 |
Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cohort Studies; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Netherlands; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Time Factors; Young Adult | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke; Sulfonamides | 2009 |
Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Propensity Score; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome | 2009 |
Another look at the results of the JUPITER trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Female; Fluorobenzenes; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Clinical trial update II: Jupiter trial, rosuvastatin has greater efficacy in elderly populations.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
The JUPITER trial: results, controversies, and implications for prevention.
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Public health. U.S. panel favors wider use of preventive drug treatment.
Topics: Advisory Committees; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Unnecessary Procedures | 2010 |
The numbers are in: statins for the primary prevention of cardiovascular disease in women.
Topics: Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Treatment Outcome | 2010 |
Is Jupiter also a god of primary prevention?
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2010 |
FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
Topics: Aged; Cardiovascular Diseases; Drug Approval; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
Summaries for patients. Rosuvastatin to prevent heart problems and stroke in persons 70 years or older.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention?
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
JUPITER, rosuvastatin, and the European Medicines Agency.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Approval; European Union; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
New analysis supports expanded use of statins in women.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; Women's Health | 2010 |
Rosuvastatin and vitamin D: might there be hypovitaminosis D on JUPITER?
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Vitamin D; Vitamin D Deficiency | 2010 |
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
Topics: Aged; Cardiovascular Diseases; Computer Simulation; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Monte Carlo Method; Pyrimidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; United States | 2010 |
Was the FDA misled by JUPITER?
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cost-Benefit Analysis; Diagnosis-Related Groups; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Markov Chains; Models, Statistical; Primary Prevention; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Rosuvastatin Calcium; South Dakota; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
[The AURORA study].
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
The JUPITER Trial: responding to the critics.
Topics: Bayes Theorem; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Public health impact of statin prescribing strategies based on JUPITER.
Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Public Health; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Switzerland; Treatment Outcome | 2011 |
Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention:
Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Interve
Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Trials by independent expert bodies.
Topics: Cardiovascular Diseases; Drug Approval; Expert Testimony; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2010 |
[The JUPITER study: background and research hypotheses].
Topics: Biomedical Research; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
[The JUPITER study: critical review of final results].
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
[JUPITER, what now?].
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease?
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2011 |
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Body Mass Index; C-Reactive Protein; Calcium; Cardiovascular Diseases; Carotid Arteries; Clinical Trials as Topic; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media; Waist Circumference | 2011 |
Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Placebos; Polymorphism, Genetic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Niacin; Ohio; Pyrimidines; Registries; Rosuvastatin Calcium; Sulfonamides; Vitamin B Complex; Young Adult | 2011 |
High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
The JUPITER trial: myth or reality?
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Outcome Assessment, Health Care; Patient Selection; Primary Prevention; Pyrimidines; Research Design; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; United States | 2011 |
A tale of three labels: translating the JUPITER trial data into regulatory claims.
Topics: Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Europe; Female; Fluorobenzenes; Government Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Translational Research, Biomedical; United States; United States Food and Drug Administration | 2011 |
A tale of five opinions (at least).
Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Regulatory divergence.
Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Translating study results to labeling.
Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Labeling; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Calcium; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Tomography, X-Ray Computed | 2011 |
[Extrapolating the NNT jeopardises biostatistics and leads to immortality].
Topics: Biostatistics; Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Numbers Needed To Treat; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Monte Carlo Method; Morbidity; Outcome Assessment, Health Care; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sweden | 2012 |
Extreme all-cause mortality in JUPITER requires reexamination of vital records.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetic Angiopathies; Early Termination of Clinical Trials; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2011 |
Is chronic severe anemia an independent predictor of poor outcomes?
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Smoking; Sulfonamides; Treatment Outcome; Triglycerides; United Kingdom | 2012 |
Therapeutic options for statin-intolerant patients.
Topics: Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Increased mortality rates in the JUPITER trial.
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Sulfonamides | 2011 |
Lipoprotein-associated phospholipase A₂ measurements: mass, activity, but little productivity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Cardiovascular Diseases; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Sulfonamides | 2012 |
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an inte
Topics: Aged; Apolipoproteins B; Blood Chemical Analysis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Pyrimidines; Reference Values; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Disease; Drug Interactions; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Statins: the good, the bad and the ugly.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pneumonia; Pyrimidines; Sulfonamides | 2012 |
Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk.
Topics: Acromegaly; Adenoma; Adult; Azetidines; Cardiovascular Diseases; Coinfection; Ezetimibe; Female; Fluorobenzenes; Hepatitis C; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Magnetic Resonance Imaging; Pituitary Neoplasms; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Balancing the cardiometabolic benefits and risks of statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Electrocardiography; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoproteins, HDL; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides | 2012 |
I am a 60-year-old woman with CAD. My LDL is 64 and my HDL is 72 on Zocor, but my doctor thinks Crestor may be better for me. He says it is more potent and could reduce my numbers even more. I would have to pay for this drug out-of-pocket. Do you thin
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Female; Fibric Acids; Fluorobenzenes; HIV Infections; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Triglycerides | 2012 |
Statins induce hyperglycaemia of uncertain importance.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Sulfonamides | 2013 |
Conflict of interest: will it ever end?
Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Clinical Trials, Phase III as Topic; Conflict of Interest; Drug Industry; Early Termination of Clinical Trials; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Motivation; Multicenter Studies as Topic; Periodicals as Topic; Platelet Aggregation Inhibitors; Pyrimidines; Reproducibility of Results; Research Support as Topic; Rosuvastatin Calcium; Sulfonamides; Ticagrelor; Truth Disclosure | 2012 |
Statin therapy: rationale for a new agent, rosuvastatin.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Female; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2002 |
52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003.
Topics: Anticoagulants; Azetidines; Benzylamines; Cardiology; Cardiovascular Diseases; Chicago; Clinical Trials as Topic; Ezetimibe; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
Using Crestor--and all statins--safely. Some simple steps can help minimize or avoid muscle problems from these cholesterol-lowering drugs.
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Pyridines; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs.
Topics: Cardiovascular Diseases; Cost Savings; Cost-Benefit Analysis; Fluorobenzenes; Forecasting; Health Care Costs; Humans; Hypolipidemic Agents; Insurance, Major Medical; Markov Chains; Models, Econometric; Pyrimidines; Rosuvastatin Calcium; Sick Leave; Sulfonamides | 2006 |
Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Topics: Adult; Aged; Cardiovascular Diseases; Costs and Cost Analysis; Female; Fluorobenzenes; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Medicare; Middle Aged; Models, Economic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2006 |
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Cardiovascular Diseases; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Psychotic Disorders; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Schizophrenia; Sulfonamides; Treatment Outcome | 2006 |
Use of high-sensitivity CRP to predict first cardiovascular events.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2007 |
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Diabetes Mellitus, Type 2; Enalapril; Endothelium, Vascular; Fatty Acids; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Arteries; Metabolic Syndrome; Oxidative Stress; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
[Statin therapy for systolic heart failure. The CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)].
Topics: Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Systole; Treatment Outcome | 2008 |
The comparative effectiveness of rosuvastatin vs. other statins in patients with an increased risk of failure to reach NCEP ATP III goal.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |